Peptides & Peptide Synthesis Products

Fmoc-Lys(Dde)-OH

Fmoc-Lys(Dde)-OH
$95.00
$95.00
Fmoc-Lys(Dde)-OH, Catalog No: 41085
(2R)-6-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid, CAS: 150629-67-7, MW: 532.63, Formula: C31H36N2O6
Catalog No: 41085
(2R)-6-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid, CAS: 150629-67-7, MW: 532.63, Formula: C31H36N2O6

* Required Fields

Description

Details

(2R)-6-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
Additional Information

Additional Information

Catalog Number 41085
CAS 150629-67-7
M.W. 532.63
Formula C31H36N2O6
IUPAC Name (2R)-6-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
Synonym No
Also Known As
  • (2R)-6-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
  • (2R)-6-[1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
  • (2R)-6-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-[(9H-fluoren-9-ylmethoxy-oxomethyl)amino]hexanoic acid
  • (2R)-6-[1-(2,6-diketo-4,4-dimethyl-cyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
  • 09765_FLUKA
  • Fmoc-D-Lys(Dde)-OH
  • Nalpha-Fmoc-Nepsilon-Dde-D-lysine
  • Nalpha-Fmoc-Nepsilon-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]-D-lysine
InChIKey ZPSRBXWVBNVFTO-RUZDIDTESA-N
InChI InChI=1S/C31H36N2O6/c1-19(28-26(34)16-31(2,3)17-27(28)35)32-15-9-8-14-25(29(36)37)33-30(38)39-18-24-22-12-6-4-10-20(22)21-11-5-7-13-23(21)24/h4-7,10-13,24-25,32H,8-9,14-18H2,1-3H3,(H,33,38)(H,36,37)/t25-/m1/s1
SMILES CC(=C1C(=O)CC(CC1=O)(C)C)NCCCC[C@H](C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
Cited Uses

Details

1. Zhong L et al, "Tether-Supported Biomembranes with Alpha-Helical Peptide-Based Anchoring Constructs", Langmuir : the ACS journal of surfaces and colloids, 29(1) pp.299-307 (2013 Jan 8).
2. Banerjee SR et al, "Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen", Angewandte Chemie (International Ed. in English), 50(39) pp.9167-9170 (2011 Sep 19).
3. Li Y et al, "Well-defined, Reversible Disulfide Cross-linked Micelles for On-demand Paclitaxel Delivery", Biomaterials, 32(27) pp.6633-6645 (2011 Sep).
4. Li Y et al, "A Novel Size-tunable Nanocarrier System for Targeted Anticancer Drug Delivery", Journal of controlled release : official journal of the Controlled Release Society, 144(3) pp.314-323 (2010 Jun 15).
5. Thomas JD et al, "Application of a Trifunctional Reactive Linker for the Construction of Antibody-Drug Hybrid Conjugates", Bioorganic & medicinal chemistry letters, 18(21) pp.5785-5788 (2008 Nov 1).
6. Ye G et al, "Synthesis and Evaluation of Tripodal Peptide Analogues for Cellular Delivery of Phosphopeptides", Journal of medicinal chemistry, 50(15) pp.3604-3617 (2007 Jul 26).
7. Kumar A et al, "Synthesis and Structure-Activity Relationships of Linear and Conformationally Constrained Peptide Analogs of CIYKYY as Src Tyrosine Kinase Inhibitors", Journal of medicinal chemistry, 49(11) pp.3395-3401 (2006 Jun 1).
8. Deliyannis G et al, "Induction of Long-Term Memory CD8+ T Cells for Recall of Viral Clearing Responses against Influenza Virus", Journal of Virology, 76(9) pp.4212-4221 (2002 May).
9. Bibbs L et al, "Strategies for the synthesis of labeled peptides", Journal of Biomolecular Techniques : JBT, 11(4) pp.155-165 (2000 Dec).
Reviews
cr